Cancer antineovascular therapy.
Oku
Naoto
N
Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526 Japan.
Asai
Tomohiro
T
Kurohane
Kohta
K
Watanabe
Koh
K
Kuromi
Koichi
K
Namba
Yukihiro
Y
Ogino
Koichi
K
Taki
Takao
T
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000008:administration & dosage* / Q000627:therapeutic use; D004337:Drug Carriers; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008081:Liposomes; D051379:Mice; D009389:Neovascularization, Pathologic; D009842:Oligopeptides; D010778:Photochemotherapy / Q000379:methods*; D011166:Porphyrins / Q000008:administration & dosage* / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D004337:Drug Carriers; D008081:Liposomes; D009842:Oligopeptides; D011166:Porphyrins; D011838:Radiation-Sensitizing Agents; C114869:dpp-cndac; C504224:benzoporphyrin D